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Abstract
Background: We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown
primary patients.
Methods: Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort
comprising 429 patients (development cohort). We identified four predictors that produced a predictive score that has been
applied to an independent multi-institutional cohort of 409 patients (validation cohort). The score was the sum of predictors
for each patient (0 to 4).
Results: The 90-day-mortality-rate was 33 and 26% in both cohorts. Multivariate analysis has identified 4 predictors for 90-
day-mortality: performance status.1 (OR=3.03, p=0.001), at least one co-morbidity requiring treatment (OR=2.68,
p=0.004), LDH.1.56the upper limit of normal (OR=2.88, p=0.007) and low albumin or protein levels (OR=3.05, p=0.007).
In the development cohort, 90-day-mortality-rates were 12.5%, 32% and 64% when the score was [0–1], 2 and [3–4],
respectively. In the validation cohort, risks were 13%, 25% and 62% according to the same score values.
Conclusions: We have validated a score that is easily calculated at the beside that estimates the 90-days mortality rate in
non-specific CUP patients. This could be helpful to identify patients who would be better served with palliative care rather
than aggressive chemotherapy.
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Introduction
Cancer of unknown primary (CUP) site represents about 2% of
all invasive cancers diagnosed in adults (in 2006, 27,860 of
1,399,790 new cancer cases in the US) [1]. CUP is defined as a
metastatic cancer with no identifiable origin at the time of
diagnosis [2]. CUP is an aggressive cancer with generally poor
outcomes; overall survival ranges from 4 to 12 months in large
series [2–8]. Nevertheless, the recognition of particular clinico-
pathologic entities and the specific treatments delivered to these
patients significantly improved CUP management [8]. More
recently, progress in immunochemistry [2–9] as well as gene
profiling [10–11] made a step forward to better CUP diagnosis.
However, these promising tools lack evidence in making impact on
patient outcome and are of little use in daily practice.
But, 80% of CUP does not fall into favorable subsets [2–4]. Non-
specific CUP treatment remains debatable, because its prognosis
remains very difficult to estimate. Several previous studies have
analyzed prognostic factors in such a population [4–7]. Neverthe-
less, these prognostic factors are not used in routine practice,
because they are not convenient to use at the bedside [8]. From a
physician’s point of view it is of major importance to discriminate
patients who would benefit from combination chemotherapy from
those who would not and would be better served by palliative care.
Due to lack of reliable tools to estimate life-expectancy, we have
conducted a new prognostic analysis in order to delineate and
validate an easily derived bedside score that predicts risk of early
death in CUP patients.
Methods
Development cohort
We retrospectively reviewed medical records of 429 consecutive
patients primarily admitted to the Oscar Lambret Cancer Centre
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consisted of patients who were diagnosed as having non-specific
CUP. Inclusion criteria were: histological proof of malignancy,
metastatic epithelial cancer, absence of identified primary site at
the time of initial diagnostic and pre-treatment work-up. In
addition, the following entities were excluded from analysis:
adenocarcinoma in an axillary lymph node in women, primary
papillary serous peritoneal carcinoma, undifferentiated carcinoma
of the mediastinum and retroperitoneum in young men (middle
line syndrome), cervical lymph nodes containing squamous
cell carcinoma. All patients underwent a basic evaluation
consisting on medical history, complete physical examination,
biopsy and histopathological examination of the most easily
accessible lesion, mammography for women, PSA levels for
men, thoracic, abdominal and pelvic computed tomography
(CT)-Scan, and, in the context of undifferentiated carcinoma the
a-feto-protein and b-human chorionic gonadotrophin levels for
both sexes [2].
Validation cohort
This cohort included non-specific CUP referred to the Cross
Cancer Institute, Edmonton, Canada from January 1998 to
December 2004 (308 cases), to Centre Le ´on Be ´rard and Hospices
Civils of Lyon, France from January 2000 to December 2004 (79
cases) and to Hospital of Lille University from January 2004 to
November 2007 (22 cases) Lille, France.
Primary endpoint
The primary endpoint was 90-day mortality. This threshold is
believed to be relevant in decision-making for advanced cancer
patients in whom the choice of whether to treat with chemother-
apy or primary palliative care need to be discussed [12–15]
Development of the score predicting the 90-day
mortality
This analysis was conducted on the development cohort. We
have first identified variables that predicted 90-day mortality using
the Student t-test. Continuous variables were analyzed using
Student t-test. Variables that predicted 90-day mortality were then
dichotomized into binary variables using receiver-operator curves
that estimated the cut-off optimizing both sensibility and
specificity. Identifying predictors of 90-day-mortality among
categorical variables was based on Chi-square tests and calculation
of odds ratios and their 95%-confidence intervals (95%-CI).
Variables significantly associated with the 90-day-mortality in
univariate analysis were then introduced into a stepwise logistic
regression model [16]. Based on these analyses we developed a
prognostic score. This score was calculated as the sum of
predictors observed for each patient (from 0 to 4). Three categories
of patients were defined: patients with high-risk of early death,
patients with intermediate risk and patients with low risk according
to observed death rates at each value of the score. Its performance
was estimated using specificity (Se), specificity (Sp), positive
predictive value (PPV), negative predictive value (NPV) and
accuracy (rate of well classified) tabulated from a classical 262
table.
Validating the model predicting 90-day mortality
This score was then applied to the validation dataset and its
performance was estimated using the classical 262 table.
Ethical Consideration
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the Oscar Lambret Cancer Center.
Data processing and analyzing
The collected data were entered into computer and analyzed
using SPSS version 13.0 statistical software.
The authors had also obtained the approval of Research Ethics
Board of Alberta Cancer Board (ETH-21853, February 2006) and
the approval of the French ‘‘Comission Nationale Informatique et
Liberte ´’’ (date of approval June 2006)’’.
Results
Study population
Development and validation cohorts are described in table 1.
Median overall survivals were respectively 189 days (range 1–
4,801) and 215 days range 1–3,842). The 90-day-mortality-rates
were respectively 142/429 (33%) and 109/409 (26%).
Predictors for 90-day mortality
This analysis was conducted on the development cohort. Three
continuous variables were not predictive for 90-day-mortality: age
(p=0.090), lymphocyte count (p=0.2206) and platelet count
(p=0.7535). Five continuous variables were predictive of 90-day
mortality and then were dichotomized into binary variables using
the cut-off value that optimized both sensibility and specificity in
ROC curves: number of metastatic sites with a cut-off fixed at.2
sites, LDH level with a cut-off fixed at.1.5 times the upper limit of
normal (ULN), alkaline phosphatase levels with a cut-off fixed
at.ULN, hemoglobin levels with a cut-off fixed at,12 g/dl,
hypoproteinemia with a cut-off fixed at,70 g/l and hypoalbu-
minemia with a cut-off fixed at,35 g/l. In further analysis,
patients with low protein or albumin levels have been combined
into a single group.
Under univariate analysis, thirteen categorical variables were
predictive for 90-day-mortality: Performance status (PS).1, at
least one co-morbidity requiring treatment, presence of lung, liver,
bone, adrenal, brain or rare metastases, presence of more than 2
metastatic sites, LDH.1.56ULN, alkaline phosphatase.ULN,
hemoglobin less than 12 g/dl and low albumin or protein levels
(Table 2). These variables were then introduced in a logistic
regression model that identified 4 independent predictive factors
for early death: PS.1, at least one co-morbidity requiring
treatment, LDH.1.56ULN and low protein or albumin
levels.
Score and performance
In the development cohort, 274 patients were fully assessable for
the four predictive factors and the primary endpoint. In order to
develop a simple and bedside model, patients with score [0–1], 2
and [3–4] points were respectively considered at low risk,
intermediate risk and high risk of 90-day mortality. Rates of 90-
day-mortality were 12.5% for ‘‘low-risk patients’’, 32% for
‘‘intermediate-risk patients’’ and 64% for ‘‘high-risk patients’’.
The 95%-confidence intervals (CI) of these three rates did not
overlap (Table 3 and Figure 1). Performance of this score for
prediction of 90-day-mortality were calculated in Table 3;
accuracy and specificity were superior to 75% with a threshold
set at score$3 (that is to say when considering patients at high risk
of 90 days mortality).
Cancer of Unknown Primary
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This score was then applied to the validation cohort. Only 174
patients were fully assessable for the four predictive factors and the
primary endpoint. The separation of patients into the three groups
was similar to that of the development cohort (Table 3 and
Figure 1). In the validation cohort, 90-day-mortality-rates were
13%, 25% and 62% according to the score (Figure 1).
Discussion
This retrospective analysis was conducted on a large database of
patients with non-specific CUP. This study has generated an easily
obtained at bedside score that estimate the risk of 90-day-mortality
in such a population. Our multivariate analysis has identified four
independent predictive factors: PS.1, presence of at least one
underlying co-morbidity requiring treatment, elevated LDH and
low albumin or protein levels. The 90-day-mortality rate in
patients having at least 3 factors was about 62–64% (see Figure 1).
This group of poor prognosis patients was well identified; the 95%-
CI of the rate did not overlap the 95%-CI of other categories (see
Figure 1). This is a reliable guidance to estimate the risk of early
death and for rational decision making shared with patient.
Patient’s characteristics were consistent with the literature on
CUP patients. The 90-day mortality was 26% (120/350) in the
Table 1. Patient’s characteristics.
Categorical data
Variables Development dataset 429 cases (%) Validation dataset 409 Cases (%)
Men 296 (68) 203 (49)
Women 133 (32) 206 (51)
PS=0 141 (33) 57 (14)
PS=1 138 (32) 129 (31)
PS=2 108 (25) 103 (25)
PS=3 35 (9) 93 (23)
PS=4 4 (1) 26 (7)
Absence of co-morbidity or co- morbidity not requiring treatment 241 (56) 264 (66)
At least 1 co-morbidity requiring treatment 172 (44) 141 (34)
Number of met. site=1 168 (39) 184 (45)
Number of met. site=2 107 (25) 130 (31)
Number of met. site=3 85 (20) 59 (14)
Number of met. site=4 43 (10) 23 (7)
Number of met. site$5 26 (6) 13 (3)
Adenocarcinoma 272 (63) 210 (51)
Undifferentiated carcinoma 58 (13) 138 (34)
Squamous cell carcinoma 77 (18) 24 (6)
Others 22 (6) 37 (9)
Lung met. 103 (24) 88 (21)
Liver met. 144 (33) 174 (42)
Bone met. 156 (36) 117 (28)
Brain met. 32 (8) 1 (0)
Continuous
Variables (units) Development dataset Median (range) Validation dataset Median (range)
Age (years) 59 (22–91) 65 (19–92)
LDH (IU/l) 660 (57–10,084) 428 (86–7,538)
Alkaline phosphatase (IU/l) 280 (31–7,423) Not done
Hemoglobin level (g/dl) 12.5 (6–17,3) 12.3 (6–18.2)
Platelets (U/mm3) 320,000 (7,000–830,000) 374,000 (10,000–736,000)
Lymphocytes (U/mm3) 1,300 (220–6,830) 1,250 (100–99,2000)
Variables Development dataset 429 cases (%) Validation dataset Cases (%)
Protein levels (g/l) 68 (49–92) 69 (42–87)
Albumin levels (g/l) 32 (14–51) 36 (19–49)
Abbreviations: PS=performance status, met.=metastasis, LDH=lactate dehydrogenase, ULN=upper limit of normal, IU: international unit, U:unit.
doi:10.1371/journal.pone.0006483.t001
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Univariate analysis Logistic regression model
Variables not introduced in multivariate analysis Odds Ratio and [95%-CI] P value - -
Men 1.03 [0.60–1.76] 0.8204 - -
Lymph nodes 0.68 [0.45–1.02] 0.063 - -
Pleural met. 1.58 [0.78–3.18] 0.2006 - -
Peritoneal met. 1.79 [0.89–3.60] 0.0980 - -
Cutaneous met. 1.36 [0.38–4.89] 0.6398 - -
Other histology than adenocarcinoma 1.03 [0.60–1.76] 0.3280 - -
Variables introduced in multivariate analysis Odds Ratio and [95%-CI] P value Adjusted Odds Ratio [95%-CI] p
PS.1 4.70 [2.91–7.61] ,0.0001 3.03 [2.64–6.81] 0.0010
At least 1 co-morbidity requiring treatment 2.04 [1.29–3.23] 0.0015 2.68 [1.47–3.47] 0.0040
Lung met. 2.94 [1.80–4.83] ,0.0001 - 0.1580
Liver met. 2.59 [1.52–4.42] 0.0004 - 0.5640
Bone met. 1.47 [0.94–2.30] 0.0084 - 0.7000
Brain met. 2.61 [1.20–5.69] 0.0038 - 0.3300
Adrenal met. 4.34 [1.07–17.68] 0.0122 - 0.8890
Rare met. 2.42 [1.48–3.97] 0.0004 - 0.3430
Number of met. Site.2 2.94 [1.86–4.65] 0.0015 - 0.4400
LDH.1.56ULN 3.18 [1.98–5.24] ,0.0001 2.88 [1.65–5.02] 0.0070
AP.ULN 2.01 [1.22–3.32] ,0.0001 - 0.8055
Hemoglobin,12 g/dl 2.67 [1.65–4.32] ,0.0001 - 0.3060
Low albumin or protein levels 3.93 [2.36–6.56] ,0.0001 3.05 [1.98–5.12] 0.0070
Abbreviations: 95%-CI: 95%-confidence intervals, PS=performance status, met.=metastasis, LDH=lactates dehydrogenase, AP=Alkaline phosphatase, ULN=upper
limit of normal.
doi:10.1371/journal.pone.0006483.t002
Figure 1. 90-day-mortality-rates and 95%-confidence intervals according to the predicitve score. LR-Dev: Low-risk patients among the
developpement cohort (score=[0–1]). LR-Val: Low-risk patients among the validation cohort (score=[0–1]). IR-Dev: Intermediate-risk patients among
the developpement cohort (score=2). IR-Val: Intermediate-risk patients among the validation cohort (score=2). HR-Dev: High-risk patients among
the developpement cohort (score=[3–4]). HR-Val: High-risk patients among the validation cohort (score=[3–4]).
doi:10.1371/journal.pone.0006483.g001
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series [6]. Culine et al. has shown that LDH levels and PS
constitute two major prognostic factors for CUP [6]. Van de Gaast
et al. has also identified PS as major prognostic factor for CUP [5].
Seve et al. has previously shown that co-morbidity was also an
important prognostic factor [17].
In the present study, LDH appears as one of the independent
predictors for 90-day mortality. Although LDH is related to tumor
burden, LDH is also high in liver diseases, in hemolysis and in
other situations with massive cells destruction. Despite its lack of
specificity, LDH remains a well-established prognostic factor for
many metastatic diseases [6,18–21].
Low albumin and protein levels are associated with both weight
loss and induction of systemic inflammatory responses. These
elements are interlinked in the metastatic setting, and hypoalbu-
minemia is a frequent biological sign of advanced disease. Serum
albumin is a well-established marker of nutritional status and
general patient status [18,21,23–24]. The prognostic value of this
parameter is also well-established [12,18,21].
Despite its subjective nature, estimation of general condition by
PS remains one of the most powerful prognostic factors in CUP
patients [5–6]. Biological markers (LDH, albumin) that constitute
more objective variables did not outperform PS in our model and
in previously published ones [5–6].
As previously reported [17–18], co-morbidity requiring treat-
ment constitutes the fourth predictor for 90-day mortality. This
relationship we believe relates to our ability to treat the patient. It
is noteworthy that in the present study and in previously published
ones that age is not a prognostic factor in CUP patients.
Nevertheless, severe underlying diseases limit our ability to
administer optimally chemotherapy. Evaluation of co-morbidities
could be done using the ACE-27 score; ACE-27.2 represented
the cut-off used in the present study [17].
This study presents several limitations due to its retrospective
nature. First of all, missing data did not allow analysis of the entire
cohorts [7]. Extensive immunohistochemical analysis and gene
profiling were not available. Several recent studies have shown the
importance of molecular and histological expertise in this field,
histological review of case must be discussed [25–27]. But despite
these modern investigations, the vast majority of CUP remains
without identifiable or highly-suspected underlying primary.
Lastly, treatments were heterogeneous across study periods and
study sites. Nevertheless, there is no consensus on treating non-
specific CUP.
To conclude, we have developed and validated a score that is
easily obtained at bedside that helps physicians to manage patients
with non-specific CUP in a more rationale way. Further studies
are required to combine this score with more current biological
parameters (such as gene profiling). Use of large multi-institutional
database could be useful to further narrow 95%-confidence
intervals of each predictor and refine their roles in the final score.
In a further analysis we plan to compare this score to the others
published predictive tools [4–7]. A randomized trial comparing
benefits of palliative chemotherapy versus best supportive care in
patients having 3 or 4 predictors for early-death should be
performed.
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